期刊
NATURE GENETICS
卷 44, 期 12, 页码 1302-1309出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ng.2434
关键词
-
资金
- US National Institutes of Health (NIH) [1DP2OD004417, 1DP2OD002177]
- NIH [NS065317, NS067354, GM084448, GM084279, GM081879, GM098101, NS39074, NS045491, NS072233, 2P01AG02074]
- Ellison Medical Foundation
- Packard Center for ALS Research at Johns Hopkins
- Consortium for Frontotemporal Research
- ALS Association
- Taube-Koret Center
- Hellman Family Foundation
- Pew Charitable Trusts
- Rita Allen Foundation Scholar
- National Center for Research Resources [RR18928]
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease primarily affecting motor neurons. Mutations in the gene encoding TDP-43 cause some forms of the disease, and cytoplasmic TDP-43 aggregates accumulate in degenerating neurons of most individuals with ALS. Thus, strategies aimed at targeting the toxicity of cytoplasmic TDP-43 aggregates may be effective. Here, we report results from two genome-wide loss-of-function TDP-43 toxicity suppressor screens in yeast. The strongest suppressor of TDP-43 toxicity was deletion of DBR1, which encodes an RNA lariat debranching enzyme. We show that, in the absence of Dbr1 enzymatic activity, intronic lariats accumulate in the cytoplasm and likely act as decoys to sequester TDP-43, preventing it from interfering with essential cellular RNAs and RNA-binding proteins. Knockdown of Dbr1 in a human neuronal cell line or in primary rat neurons is also sufficient to rescue TDP-43 toxicity. Our findings provide insight into TDP-43 mediated cytotoxicity and suggest that decreasing Dbr1 activity could be a potential therapeutic approach for ALS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据